The Prognostic Impact of Radioiodine Therapy in Patients with Papillary Thyroid Cancer
Hormone and Metabolic Research · 01.11.2024 · 56 (11) · 770-778
DOI: 10.1055/a-2423-4849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.11.2024. Verfasst von Matthias Schott und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division for Specific Endocrinology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Cancer, Papillary, Thyroid Neoplasms, SEER Program. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Radioiodine (RAI) therapy after surgery, is an important component for the treatment of patients with papillary thyroid cancer (PTC), the most common thyroid cancer. In this study we sought to evaluate the cancer-specific survival (CSS) impact of RAI in specific thyroid cancer subgroups. The Surveillance, Epidemiology, and End Results (SEER) database were used to identify patients with PTC who underwent surgery between 2000 and 2019. Patients not treated with RAI were compared to those treated with RAI using propensity score matching (PSM) on the basis of identical inclusion criteria. A total of 106 333 patients were identified from the SEER database. RAI therapy was associated with improved CSS in the matched cohort (HR: 0.83; 95% CI: 0.72–0.96, p=0.01) but not in the unmatched data set (HR: 1.46; 95% CI: 1.30–1.64, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division for Specific Endocrinology, Medical Faculty, University of Duesseldorf, Duesseldorf, Germany.
- Department of Inclusive Medicine, University Hospital Ostwestfalen-Lippe, Bielefeld University, Bielefeld, Germany.
- Department of General and Visceral Surgery, Thoracic Surgery and Proctology, University Hospital Herford, Medical Campus OWL, Ruhr University Bochum, Herford, Germany.
- Department of Diagnostic and Interventional Radiology and Neuroradiology, Klinikum Herford, Herford, Germany.
Zitieren
APA
Schott, M., Schott-Ohly, P., Krieg, S., Thomaschky, C., Wieltsch, J. H., Petrovitch, A., & Krieg, A. (2024). The Prognostic Impact of Radioiodine Therapy in Patients with Papillary Thyroid Cancer. Hormone and Metabolic Research, 56(11), 770-778. https://doi.org/10.1055/a-2423-4849
Vancouver
Schott M, Schott-Ohly P, Krieg S, Thomaschky C, Wieltsch JH, Petrovitch A, et al. The Prognostic Impact of Radioiodine Therapy in Patients with Papillary Thyroid Cancer. Hormone and Metabolic Research. 2024;56(11):770-778. doi:10.1055/a-2423-4849
BibTeX
@article{Schott2024,
author = {Schott, Matthias and Schott-Ohly, Patricia and Krieg, Sarah and Thomaschky, Cora and Wieltsch, Jan-Hendrik and Petrovitch, Alexander and Krieg, Andreas},
title = {The Prognostic Impact of Radioiodine Therapy in Patients with Papillary Thyroid Cancer},
journal = {Hormone and Metabolic Research},
year = {2024},
volume = {56},
number = {11},
pages = {770--778},
doi = {10.1055/a-2423-4849}
}
EUVIMED